EUCTR2009-015970-36-ES进行中（未招募）不适用
Ensayo fase II abierto, comparativo, aleatorizado y multicéntrico que compara la eficacia y tolerabilidad de Olaparib en combinación con Paclitaxel y Carboplatino versus Paclitaxel y Carboplatino solos en pacientes con carcinoma seroso de ovario avanzado platino sensible. A Phase II, Open-Label, Randomised, Comparative, Multicentre Study to Compare the Efficacy and tolerability of Olaparib in combination with Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel Alone in Patients with Platinum Sensitive Advanced Serous Ovarian Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Provision of fully informed consent prior to any study specific procedures
- •2. Patients must be >/= 18 years of age.
- •3. Histologically or cytologically diagnosed ovarian cancer with a serous histology or a serous component, including primary peritoneal and fallopian tube cancer.
- •4. Patients who have received no more than 3 previous platinum containing regimens and were progression free, in the opinion of the Investigator, for a minimum of 6 months following completion of their last platinum containing regimen, prior to randomisation in the study.
- •5. At least one lesion, not previously irradiated, that can be accurately measured at baseline as >/= 10 mm in the longest diameter (except lymph nodes which must have short axis >/= 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and which is suitable for accurate repeated measurements.
- •6. Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment as defined below:
- •- Haemoglobin >/= 9.0 g/dL
- •- Absolute neutrophil count (ANC) >/= 1.5 x 109/L
- •- White blood cells (WBC) > 3x109/L
- •- Platelet count >/= 100 x 109/L
- •- Total bilirubin - AST (SGOT)/ALT (SGPT) - Serum creatinine - Creatinine clearance (using Cockcroft-Gault) within normal range (> 50 mL/min)
- •7. ECOG performance status 8. Patients must have a life expectancy >/= 12 weeks.
- •9. Evidence of non-childbearing status for women of childbearing potential, or postmenopausal status: negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on day 1
- •Postmenopausal is defined as one of the following:
- •- Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments,
- •- LH and FSH levels in the post menopausal range for women under 50,
- •- radiation-induced oophorectomy with last menses >1 year ago,
- •- chemotherapy-induced menopause with >1 year interval since last menses,
- •- or surgical sterilisation (bilateral oophorectomy or hysterectomy).
- •10. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients receiving any systemic anticancer chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used). The patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment.
- •2. Patients with second primary cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, Ductal Carcinoma in Situ (DCIS), stage 1 grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for >/= 5 years.
- •3. Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment.
- •4. Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
- •5. Patients with severe hypersensitivity reactions to paclitaxel, macrogolglycerol ricinoleate (polyoxyl castor oil) or to any of the excipients in paclitaxel.
- •6. Patients with a known hypersensitivity to olaparib or any of the excipients of the products
- •7. Patients with a history of severe allergic reaction to carboplatin or other platinum containing compounds. Patients who require desensitisation procedures for further platinum-based treatment should not be included.
- •8. Hypersensitivity to pre-medications required for treatment with carboplatin / paclitaxel.
- •9. Any previous treatment with a PARP inhibitor, including olaparib.
- •10. Patients receiving inhibitors of CYP3A4.
- •11. Persisting toxicities (>CTCAE grade 2) caused by previous cancer therapy.
- •12. Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
- •13. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- •14. Breast feeding women.
- •15. known immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV).
- •16. Patients with known active hepatic disease (i.e., Hepatitis B or C).
- •17. Patients with uncontrolled seizures.
- •18. Previous randomisation in this study.
- •19. Participation in another clinical study with an investigational product during the last 14 days.
- •20. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
研究者
相似试验
进行中（未招募）
1 期
Ensayo de faseII, abierto, aleatorizado para evaluar la eficacia y seguridad de AZD6244 versus capecitabina (XelodaTM) en pacientes con cáncer colorrectal que han fracasado a una o dos líneas previas de quimioterapia.Cáncer colorrectal metastáticoEUCTR2006-001457-10-ESAstraZeneca AB64
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, abierto (con grupos de control enmascarados de activador del plasminógeno y placebo) para evaluar los efectos de distintos regímenes de infusión intratrombo de plasmina (humana) en comparación con activador del plasminógeno y placebo en pacientes con oclusión aguda de una arteria nativa de las extremidades inferiores o de un injerto de derivacióEUCTR2010-019760-36-ESTalecris Biotherapeutics, Incorporated100
进行中（未招募）
1 期
Estudio de fase II exploratorio, abierto, aleatorizado, multicéntrico para evaluar la eficacia y seguridad de la combinación de panitumumab con quimioterapia FOLFOX 4 o panitumumab con quimioterapia FOLFIRI en sujetos con cáncer colorrectal con KRAS no mutado y metástasis solo hepáticas. - PLANETEUCTR2008-006766-28-ESGrupo de Tratamiento de los Tumores Digestivos - TTD80
进行中（未招募）
1 期
Estudio de fase II, aleatorizado, abierto y controlado para evaluar la seguridad e inmunogenicidad de diferentes formulaciones de una vacuna experimental frente a la gripe pandémica (formulación con virus fraccionados adyuvada en AS03) administrada con un esquema de dos dosis (intervalo de 21 días) en niños de entre 3 y 9 años de edad.A phase II, randomized, open, controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age. - H5N1-009, H5N1-022 STG 009 cohort 2, H5N1-023 STG 009 cohort 3EUCTR2006-001168-22-ESGlaxoSmithKline S.A.405
进行中（未招募）
不适用
Ensayo de fase II, no randomizado, abierto, unicéntrico, de quimioterapia intraarterial con melfalán para el tratamiento del retinoblastoma (RTB) en fase intraocular avanzada. Phase II trial, no randomized, open, one centre, of intraarterial quimiotherapy with melfalan for the treatement of retinoblastoma (RTB) in advanced intraocular phase.RETINOBLASTOMA UNILATERAL AVANZADOADVANCED INTRAOCULAR RETINOBLASTOMAEUCTR2009-010737-47-ESHOSPITAL SANT JOAN DE DÉ